JP2020090507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020090507A5 JP2020090507A5 JP2020002531A JP2020002531A JP2020090507A5 JP 2020090507 A5 JP2020090507 A5 JP 2020090507A5 JP 2020002531 A JP2020002531 A JP 2020002531A JP 2020002531 A JP2020002531 A JP 2020002531A JP 2020090507 A5 JP2020090507 A5 JP 2020090507A5
- Authority
- JP
- Japan
- Prior art keywords
- left ventricular
- cardiotoxicity
- lvef
- breast cancer
- trastuzumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010048610 Cardiotoxicity Diseases 0.000 claims 49
- 231100000259 cardiotoxicity Toxicity 0.000 claims 49
- 206010019280 Heart failures Diseases 0.000 claims 33
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 33
- 239000003814 drug Substances 0.000 claims 31
- 229960000575 trastuzumab Drugs 0.000 claims 31
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 30
- 230000002861 ventricular Effects 0.000 claims 29
- 229960002087 pertuzumab Drugs 0.000 claims 21
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 19
- 239000002246 antineoplastic agent Substances 0.000 claims 19
- 229940127089 cytotoxic agent Drugs 0.000 claims 19
- 229960003668 docetaxel Drugs 0.000 claims 19
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 17
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 16
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 16
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 13
- 230000007681 cardiovascular toxicity Effects 0.000 claims 12
- 238000002203 pretreatment Methods 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 230000007423 decrease Effects 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940123237 Taxane Drugs 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 238000001815 biotherapy Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022000876A JP2022062010A (ja) | 2011-10-14 | 2022-01-06 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547535P | 2011-10-14 | 2011-10-14 | |
| US61/547,535 | 2011-10-14 | ||
| US201161567015P | 2011-12-05 | 2011-12-05 | |
| US61/567,015 | 2011-12-05 | ||
| US201261657669P | 2012-06-08 | 2012-06-08 | |
| US61/657,669 | 2012-06-08 | ||
| US201261682037P | 2012-08-10 | 2012-08-10 | |
| US61/682,037 | 2012-08-10 | ||
| US201261694584P | 2012-08-29 | 2012-08-29 | |
| US61/694,584 | 2012-08-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182187A Division JP6646785B1 (ja) | 2011-10-14 | 2019-10-02 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000876A Division JP2022062010A (ja) | 2011-10-14 | 2022-01-06 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020090507A JP2020090507A (ja) | 2020-06-11 |
| JP2020090507A5 true JP2020090507A5 (https=) | 2020-08-27 |
Family
ID=47073543
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535859A Withdrawn JP2014530235A (ja) | 2011-10-14 | 2012-10-11 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2017125883A Withdrawn JP2017222663A (ja) | 2011-10-14 | 2017-06-28 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2019182187A Active JP6646785B1 (ja) | 2011-10-14 | 2019-10-02 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2020002531A Withdrawn JP2020090507A (ja) | 2011-10-14 | 2020-01-10 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2022000876A Withdrawn JP2022062010A (ja) | 2011-10-14 | 2022-01-06 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2023075388A Active JP7303957B1 (ja) | 2011-10-14 | 2023-05-01 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2023075391A Active JP7352760B2 (ja) | 2011-10-14 | 2023-05-01 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2023150231A Withdrawn JP2024009803A (ja) | 2011-10-14 | 2023-09-15 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2025170896A Pending JP2026028254A (ja) | 2011-10-14 | 2025-10-09 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535859A Withdrawn JP2014530235A (ja) | 2011-10-14 | 2012-10-11 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2017125883A Withdrawn JP2017222663A (ja) | 2011-10-14 | 2017-06-28 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2019182187A Active JP6646785B1 (ja) | 2011-10-14 | 2019-10-02 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000876A Withdrawn JP2022062010A (ja) | 2011-10-14 | 2022-01-06 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2023075388A Active JP7303957B1 (ja) | 2011-10-14 | 2023-05-01 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2023075391A Active JP7352760B2 (ja) | 2011-10-14 | 2023-05-01 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2023150231A Withdrawn JP2024009803A (ja) | 2011-10-14 | 2023-09-15 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
| JP2025170896A Pending JP2026028254A (ja) | 2011-10-14 | 2025-10-09 | Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品 |
Country Status (30)
| Country | Link |
|---|---|
| US (9) | US20130095172A1 (https=) |
| EP (7) | EP4234033B1 (https=) |
| JP (9) | JP2014530235A (https=) |
| KR (5) | KR20240109285A (https=) |
| CN (8) | CN116271013A (https=) |
| AU (4) | AU2012322797B2 (https=) |
| BR (1) | BR112014007521A8 (https=) |
| CL (1) | CL2014000889A1 (https=) |
| DK (4) | DK4403228T3 (https=) |
| EA (1) | EA034390B1 (https=) |
| ES (4) | ES3023516T3 (https=) |
| FI (3) | FI4234033T3 (https=) |
| HK (1) | HK1202242A1 (https=) |
| HR (1) | HRP20191247T1 (https=) |
| HU (1) | HUE044352T2 (https=) |
| IL (5) | IL309917A (https=) |
| IN (1) | IN2014CN02703A (https=) |
| LT (4) | LT4403228T (https=) |
| MX (2) | MX2014004021A (https=) |
| MY (2) | MY194408A (https=) |
| PE (1) | PE20142363A1 (https=) |
| PH (2) | PH12014500733B1 (https=) |
| PL (4) | PL4241849T3 (https=) |
| PT (4) | PT4241849T (https=) |
| RS (1) | RS58944B1 (https=) |
| SG (3) | SG10202110077QA (https=) |
| SI (4) | SI4241849T1 (https=) |
| UA (2) | UA123092C2 (https=) |
| WO (1) | WO2013055874A2 (https=) |
| ZA (1) | ZA201401259B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| AU2009320481C1 (en) | 2008-11-03 | 2016-12-08 | Syntarga B.V. | Novel CC-1065 analogs and their conjugates |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AU2011243294C1 (en) | 2010-04-21 | 2015-12-03 | Syntarga B.V. | Novel conjugates of CC-1065 analogs and bifunctional linkers |
| WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| EA031077B1 (ru) * | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2015095404A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| CN104726462A (zh) * | 2013-12-20 | 2015-06-24 | 北京天广实生物技术股份有限公司 | 抗her2人源化抗体mil41、其制备方法及用途 |
| AU2015205574B2 (en) | 2014-01-10 | 2019-08-15 | Byondis B.V. | Method for purifying Cys-linked antibody-drug conjugates |
| CN105899236B (zh) * | 2014-01-10 | 2019-07-26 | 斯索恩生物制药有限公司 | 表现出改进的体内抗肿瘤活性的倍癌霉素adc |
| HUE029672T2 (en) * | 2014-01-10 | 2017-03-28 | Synthon Biopharmaceuticals Bv | Duokarmicin-ADCs for use in the treatment of endometrial cancer |
| WO2016094341A1 (en) * | 2014-12-08 | 2016-06-16 | Synta Pharmaceuticals Corp. | Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer |
| KR102067327B1 (ko) * | 2015-05-29 | 2020-02-11 | 익스프레션 패톨로지, 인크. | 최적의 암 치료를 위한 Her2 단백질 정량 |
| JP6896650B2 (ja) | 2015-06-17 | 2021-06-30 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法 |
| WO2016207091A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use |
| MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
| AU2017355432A1 (en) * | 2016-11-04 | 2019-05-16 | F. Hoffmann-La Roche Ag | Treatment of HER2-positive breast cancer |
| AU2017387909A1 (en) * | 2016-12-28 | 2019-06-27 | Genentech, Inc. | Treatment of advanced HER2 expressing cancer |
| SG11201905622VA (en) | 2017-01-17 | 2019-08-27 | Genentech Inc | Subcutaneous her2 antibody formulations |
| US11077189B2 (en) * | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| KR102267593B1 (ko) * | 2018-10-19 | 2021-06-21 | 주식회사 프로티나 | Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법 |
| CA3125302A1 (en) * | 2019-01-18 | 2020-07-23 | University Of Southern California | Methods and compositions to improve the safety and efficacy of cellular therapies |
| CN114144169A (zh) * | 2019-05-27 | 2022-03-04 | 托尔玛国际有限公司 | 醋酸亮丙瑞林组合物和使用其治疗乳腺癌的方法 |
| ES3049663T3 (en) * | 2019-06-28 | 2025-12-17 | Univ Texas | Method of reconstituting liposomal annamycin |
| KR20220027969A (ko) | 2019-06-28 | 2022-03-08 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 프리리포솜 아나마이신 동결건조물의 제조 |
| AU2020381495A1 (en) * | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| WO2021222068A1 (en) * | 2020-04-29 | 2021-11-04 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for detecting gene fusions of esr1 and ccdc170 for determining increased resistance to endocrine therapy and for cancer treatment |
| CN111710425A (zh) * | 2020-06-19 | 2020-09-25 | 复旦大学附属中山医院 | 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置 |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
| MX2024006978A (es) * | 2021-12-07 | 2024-07-19 | Io Therapeutics Inc | Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+. |
Family Cites Families (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE97498T1 (de) | 1984-01-30 | 1993-12-15 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| CA1339946C (en) | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech, Inc., South San Francisco, Calif. | Her2 extrazellulare domäne |
| DE68926248T2 (de) | 1989-09-29 | 1996-12-19 | Oncogene Science Inc | p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| EP0950067B1 (en) | 1996-11-27 | 2007-08-29 | Genentech, Inc. | Affinity purification of polypeptide on protein a matrix |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| JP2002507404A (ja) | 1998-03-27 | 2002-03-12 | ジェネンテク・インコーポレイテッド | Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用 |
| PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| JP5623681B2 (ja) | 1999-05-14 | 2014-11-12 | ジェネンテック， インコーポレイテッド | 抗−ＥｒｂＢ２抗体による治療 |
| IL147017A0 (en) | 1999-06-25 | 2002-08-14 | Genentech Inc | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| CA2376596C (en) | 1999-06-25 | 2009-10-06 | Genentech, Inc. | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| TR200200472T2 (tr) | 1999-08-27 | 2002-06-21 | Genentech, Inc. | Anti-Erb B2 antikorları ile tedavi için dozajlar |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US20200048362A1 (en) | 2000-03-16 | 2020-02-13 | Immunogen, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
| US20030232399A1 (en) | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| NZ526720A (en) | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| US20030040509A1 (en) | 2001-08-06 | 2003-02-27 | Genomed, Llc | Methods and compositions for treating diseases associated with excesses in ACE |
| EP1300146A1 (en) | 2001-10-03 | 2003-04-09 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for the treatment of animal mammary tumors |
| US20040048525A1 (en) | 2002-01-28 | 2004-03-11 | Sagucio Esteban N. | Watercycle for wet rider |
| US7435797B2 (en) | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
| HRPK20041072B3 (hr) | 2002-05-17 | 2007-07-31 | Aventis Pharma S.A. | Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika |
| ES2392525T3 (es) | 2002-07-15 | 2012-12-11 | F. Hoffmann-La Roche Ag | Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4 |
| SI1543038T2 (sl) | 2002-09-11 | 2020-12-31 | Genentech, Inc. | Čiščenje proteinov |
| US20060100168A1 (en) * | 2002-09-30 | 2006-05-11 | The Trustee Of Boston University | Method of treating cancer using adenosine and its analogs |
| JP2006516117A (ja) | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療 |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| US20050025753A1 (en) | 2003-04-30 | 2005-02-03 | Wei Han | Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells |
| EP1648940B1 (en) | 2003-07-28 | 2016-04-27 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| JP4969440B2 (ja) | 2004-04-08 | 2012-07-04 | デビッド， ビー． エイガス， | 疼痛治療のためのＥｒｂＢアンタゴニスト |
| EP1755673B1 (en) | 2004-04-12 | 2014-07-23 | MedImmune, LLC | Anti-il-9 antibody formulations and uses thereof |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| US20050280299A1 (en) | 2004-06-18 | 2005-12-22 | Alfmeier Corporation | Mounting adaptor for seat assembly, and seat assembly having mounting adaptor |
| KR20140032004A (ko) | 2004-07-22 | 2014-03-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| KR20070057839A (ko) | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RU2007114111A (ru) * | 2004-11-04 | 2008-12-10 | Пфайзер Продактс Инк. (Us) | Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы |
| JP2008523073A (ja) | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| WO2006096861A2 (en) | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| MY157955A (en) | 2005-07-06 | 2016-08-30 | Hoffmann La Roche | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| CA2652999A1 (en) | 2006-05-31 | 2007-12-13 | Thallion Pharmaceuticals Incorporated | Methods, compositions, and kits for treating shiga toxin associated conditions |
| JP2009539836A (ja) * | 2006-06-05 | 2009-11-19 | ジェネンテック・インコーポレーテッド | ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長 |
| JP5305904B2 (ja) | 2006-06-14 | 2013-10-02 | 株式会社キャタラー | 排ガス浄化用触媒 |
| DK2056874T3 (da) | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
| WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| MX2009008981A (es) * | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| EP1997534A1 (en) | 2007-05-31 | 2008-12-03 | Pierre Fabre Medicament | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
| MX2009012838A (es) | 2007-06-06 | 2009-12-11 | Hoffmann La Roche | Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo. |
| EP2171090B1 (en) | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| WO2009051815A1 (en) | 2007-10-19 | 2009-04-23 | Bipar Sciences, Inc. | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors |
| CN101889025B (zh) | 2007-10-30 | 2013-11-13 | 健泰科生物技术公司 | 通过阳离子交换层析进行的抗体纯化 |
| CN103169973A (zh) | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US20090203015A1 (en) * | 2008-02-13 | 2009-08-13 | Celera Corporation | Multiplex assays for hormonal and growth factor receptors, and uses thereof |
| EP2260056A1 (en) | 2008-03-06 | 2010-12-15 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| NZ602675A (en) | 2008-03-18 | 2014-03-28 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| US9235334B2 (en) | 2008-05-09 | 2016-01-12 | Genesis Industries, Llc | Managing landbases and machine operations performed thereon |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| WO2010042705A1 (en) | 2008-10-09 | 2010-04-15 | Medimmune, Llc | Antibody formulation |
| KR101807319B1 (ko) * | 2008-11-22 | 2017-12-11 | 제넨테크, 인크. | 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도 |
| MX2011009312A (es) | 2009-03-06 | 2012-02-29 | Medimmune Llc | Formulaciones de anticuerpos humanizados anti-cd19. |
| EP2435071A1 (en) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| ES2570569T3 (es) | 2009-09-28 | 2016-05-19 | Hoffmann La Roche | Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso |
| US20110165155A1 (en) | 2009-12-04 | 2011-07-07 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| BR112013014316A2 (pt) | 2010-12-09 | 2016-09-27 | Genentech Inc | tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1 |
| JP6385060B2 (ja) | 2011-03-07 | 2018-09-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 治療的に活性な抗体のインビボにおける選択 |
| WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
| US20130195851A1 (en) | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
| WO2013182668A1 (en) | 2012-06-08 | 2013-12-12 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| DK2884979T3 (da) | 2012-08-17 | 2019-09-02 | Hoffmann La Roche | Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib |
| KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| WO2015095404A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| JP2017513901A (ja) | 2014-04-25 | 2017-06-01 | ジェネンテック， インコーポレイテッド | トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法 |
| KR20240129101A (ko) | 2015-07-07 | 2024-08-27 | 제넨테크, 인크. | 항-her2 항체-약물 접합체 및 bcl-2 억제제를 사용한 병용 요법 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| AU2017355432A1 (en) | 2016-11-04 | 2019-05-16 | F. Hoffmann-La Roche Ag | Treatment of HER2-positive breast cancer |
| AU2017387909A1 (en) | 2016-12-28 | 2019-06-27 | Genentech, Inc. | Treatment of advanced HER2 expressing cancer |
| SG11201905622VA (en) | 2017-01-17 | 2019-08-27 | Genentech Inc | Subcutaneous her2 antibody formulations |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| TW201927288A (zh) | 2017-10-20 | 2019-07-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | 適用於治療之微脂體ｒｎａ配製物的製備及儲存 |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
| MX2023000622A (es) | 2020-07-14 | 2023-02-22 | Genentech Inc | Ensayos para combinaciones de dosis fija. |
| EP4259662A1 (en) | 2020-12-11 | 2023-10-18 | Genentech, Inc. | Combination therapies for treatment of her2 cancer |
| IL315153A (en) | 2022-03-14 | 2024-10-01 | Genentech Inc | Combined treatments for breast cancer |
-
2012
- 2012-10-11 WO PCT/US2012/059683 patent/WO2013055874A2/en not_active Ceased
- 2012-10-11 DK DK24174637.9T patent/DK4403228T3/da active
- 2012-10-11 EP EP23172794.2A patent/EP4234033B1/en active Active
- 2012-10-11 SG SG10202110077Q patent/SG10202110077QA/en unknown
- 2012-10-11 JP JP2014535859A patent/JP2014530235A/ja not_active Withdrawn
- 2012-10-11 ES ES23172794T patent/ES3023516T3/es active Active
- 2012-10-11 MX MX2014004021A patent/MX2014004021A/es active IP Right Grant
- 2012-10-11 HR HRP20191247TT patent/HRP20191247T1/hr unknown
- 2012-10-11 MY MYPI2019003795A patent/MY194408A/en unknown
- 2012-10-11 DK DK23172847.8T patent/DK4241849T3/da active
- 2012-10-11 IL IL309917A patent/IL309917A/en unknown
- 2012-10-11 ES ES24174637T patent/ES3045013T3/es active Active
- 2012-10-11 EP EP23172847.8A patent/EP4241849B1/en active Active
- 2012-10-11 LT LTEP24174637.9T patent/LT4403228T/lt unknown
- 2012-10-11 PT PT231728478T patent/PT4241849T/pt unknown
- 2012-10-11 PT PT241746379T patent/PT4403228T/pt unknown
- 2012-10-11 ES ES23172847T patent/ES2993341T3/es active Active
- 2012-10-11 PL PL23172847.8T patent/PL4241849T3/pl unknown
- 2012-10-11 AU AU2012322797A patent/AU2012322797B2/en active Active
- 2012-10-11 MY MYPI2014001060A patent/MY172326A/en unknown
- 2012-10-11 EP EP24174637.9A patent/EP4403228B1/en active Active
- 2012-10-11 KR KR1020247021013A patent/KR20240109285A/ko active Pending
- 2012-10-11 DK DK23172794.2T patent/DK4234033T3/da active
- 2012-10-11 UA UAA201709999A patent/UA123092C2/uk unknown
- 2012-10-11 ES ES12778010T patent/ES2736005T3/es active Active
- 2012-10-11 DK DK12778010.4T patent/DK2766040T3/da active
- 2012-10-11 US US13/649,591 patent/US20130095172A1/en not_active Abandoned
- 2012-10-11 CN CN202310108240.2A patent/CN116271013A/zh active Pending
- 2012-10-11 EA EA201490779A patent/EA034390B1/ru active Protection Beyond IP Right Term
- 2012-10-11 IL IL301603A patent/IL301603A/en unknown
- 2012-10-11 CN CN201811518146.XA patent/CN109908341B/zh active Active
- 2012-10-11 KR KR1020147009738A patent/KR102099991B1/ko active Active
- 2012-10-11 SI SI201232077T patent/SI4241849T1/sl unknown
- 2012-10-11 CN CN202310820523.XA patent/CN117018187A/zh active Pending
- 2012-10-11 EP EP19165341.9A patent/EP3598981A3/en not_active Withdrawn
- 2012-10-11 SG SG11201401432XA patent/SG11201401432XA/en unknown
- 2012-10-11 BR BR112014007521A patent/BR112014007521A8/pt not_active Application Discontinuation
- 2012-10-11 PH PH1/2014/500733A patent/PH12014500733B1/en unknown
- 2012-10-11 LT LTEP12778010.4T patent/LT2766040T/lt unknown
- 2012-10-11 PL PL24174637.9T patent/PL4403228T3/pl unknown
- 2012-10-11 SI SI201232097T patent/SI4403228T1/sl unknown
- 2012-10-11 PL PL12778010T patent/PL2766040T3/pl unknown
- 2012-10-11 CN CN202310064889.9A patent/CN116271011B/zh active Active
- 2012-10-11 CN CN201280061896.3A patent/CN104334189A/zh active Pending
- 2012-10-11 PE PE2014000507A patent/PE20142363A1/es active IP Right Grant
- 2012-10-11 LT LTEP23172794.2T patent/LT4234033T/lt unknown
- 2012-10-11 HK HK15102729.7A patent/HK1202242A1/xx unknown
- 2012-10-11 FI FIEP23172794.2T patent/FI4234033T3/fi active
- 2012-10-11 EP EP25181690.6A patent/EP4635572A3/en active Pending
- 2012-10-11 KR KR1020237015216A patent/KR102770098B1/ko active Active
- 2012-10-11 IN IN2703CHN2014 patent/IN2014CN02703A/en unknown
- 2012-10-11 SG SG10201606756PA patent/SG10201606756PA/en unknown
- 2012-10-11 SI SI201231637T patent/SI2766040T1/sl unknown
- 2012-10-11 PT PT12778010T patent/PT2766040T/pt unknown
- 2012-10-11 LT LTEP23172847.8T patent/LT4241849T/lt unknown
- 2012-10-11 PL PL23172794.2T patent/PL4234033T3/pl unknown
- 2012-10-11 EP EP12778010.4A patent/EP2766040B1/en not_active Revoked
- 2012-10-11 EP EP23172860.1A patent/EP4234034A3/en not_active Withdrawn
- 2012-10-11 PT PT231727942T patent/PT4234033T/pt unknown
- 2012-10-11 FI FIEP24174637.9T patent/FI4403228T3/fi active
- 2012-10-11 CN CN202310701159.5A patent/CN116808199A/zh active Pending
- 2012-10-11 FI FIEP23172847.8T patent/FI4241849T3/fi active
- 2012-10-11 CN CN202210486683.0A patent/CN114984205A/zh active Pending
- 2012-10-11 KR KR1020237005562A patent/KR102679155B1/ko active Active
- 2012-10-11 KR KR1020177004681A patent/KR102502545B1/ko active Active
- 2012-10-11 HU HUE12778010 patent/HUE044352T2/hu unknown
- 2012-10-11 RS RS20190845A patent/RS58944B1/sr unknown
- 2012-10-11 CN CN202310135044.4A patent/CN116236569A/zh active Pending
- 2012-10-11 SI SI201232088T patent/SI4234033T1/sl unknown
- 2012-11-10 UA UAA201405091A patent/UA116095C2/uk unknown
-
2014
- 2014-02-19 ZA ZA2014/01259A patent/ZA201401259B/en unknown
- 2014-03-06 IL IL231350A patent/IL231350B2/en unknown
- 2014-04-03 MX MX2019009153A patent/MX2019009153A/es unknown
- 2014-04-09 CL CL2014000889A patent/CL2014000889A1/es unknown
-
2016
- 2016-03-02 US US15/058,520 patent/US20160175438A1/en not_active Abandoned
- 2016-07-15 AU AU2016204962A patent/AU2016204962B2/en active Active
-
2017
- 2017-06-28 JP JP2017125883A patent/JP2017222663A/ja not_active Withdrawn
-
2018
- 2018-06-05 AU AU2018203970A patent/AU2018203970B2/en active Active
- 2018-09-06 US US16/123,809 patent/US20190117769A1/en not_active Abandoned
-
2019
- 2019-03-11 PH PH12019500519A patent/PH12019500519A1/en unknown
- 2019-10-02 JP JP2019182187A patent/JP6646785B1/ja active Active
- 2019-11-04 AU AU2019261666A patent/AU2019261666B2/en active Active
-
2020
- 2020-01-10 JP JP2020002531A patent/JP2020090507A/ja not_active Withdrawn
- 2020-02-20 US US16/796,163 patent/US20200206348A1/en not_active Abandoned
- 2020-08-13 US US16/992,966 patent/US20210015919A1/en not_active Abandoned
- 2020-08-17 US US16/994,950 patent/US20200376120A1/en not_active Abandoned
-
2021
- 2021-10-03 IL IL286921A patent/IL286921A/en unknown
-
2022
- 2022-01-06 JP JP2022000876A patent/JP2022062010A/ja not_active Withdrawn
- 2022-03-28 US US17/656,732 patent/US20220362379A1/en not_active Abandoned
-
2023
- 2023-04-28 US US18/309,452 patent/US12527867B2/en active Active
- 2023-04-28 US US18/309,488 patent/US20230277664A1/en not_active Abandoned
- 2023-05-01 JP JP2023075388A patent/JP7303957B1/ja active Active
- 2023-05-01 JP JP2023075391A patent/JP7352760B2/ja active Active
- 2023-09-15 JP JP2023150231A patent/JP2024009803A/ja not_active Withdrawn
-
2025
- 2025-09-25 IL IL323574A patent/IL323574A/en unknown
- 2025-10-09 JP JP2025170896A patent/JP2026028254A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020090507A5 (https=) | ||
| Bahleda et al. | Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors | |
| Farkowski et al. | Comparative effectiveness and safety of antazoline-based and propafenone-based strategies for pharmacological cardioversion of short-duration atrial fibrillation in the emergency department | |
| JP2025148449A5 (https=) | ||
| BR9809694A (pt) | Processo e composição para administração de taxanos oralmente a pacientes humanos | |
| Imamura et al. | Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure | |
| JP2013060447A (ja) | ボーラスまたは間欠的な静脈内注入による、抗内毒素薬の投与 | |
| RU2539394C1 (ru) | Способ лечения стерномедиастинита | |
| Allama et al. | Levosimendan vs intra-aortic balloon pump in low ejection fraction coronary artery bypass grafting patients | |
| RU2465843C1 (ru) | Способ адъювантной терапии местно-распространенного рака желудка | |
| RU2547999C1 (ru) | Способ лечения аденогенного местно-распространенного рака нижнеампулярного отдела прямой кишки | |
| Baghi et al. | Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck | |
| Okumura et al. | Two cases of dilated cardiomyopathy with blood pressure-limited tolerability of cardioprotective agents improved by ivabradine | |
| Rizzo et al. | Efficacy of autovaccination therapy on post-coronary artery bypass grafting methicillin-resistant Staphylococcus aureus mediastinitis | |
| Larouche et al. | Corticosteroids and serious cytarabine‐induced pulmonary edema | |
| Lee et al. | Late thrombotic occlusion of paclitaxel eluting stent more than one year after stent implantation | |
| RU2424013C1 (ru) | Способ лечения рака прямой кишки | |
| US10953063B2 (en) | Method of treating select cancers using timed administration of plant extract from species Physalis pubescens and Hedyotis diffusa willd | |
| Papadopoulos et al. | CTNI-10. A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN: TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN ADAMANTINOMATOUS CRANIOPHARYNGIOMA (ACP) PATIENTS | |
| Batnyam et al. | Short course of amiodarone-induced severe lung toxicity in post-CABG patient | |
| Ng et al. | Old but not Vain: Two Cases of Refractory Polymorphic Ventricular Tachycardia associated with Coronary Artery Disease successfully treated with Quinidine | |
| RU2468836C1 (ru) | Способ лечения местнораспространенного неоперабельного рака пищевода | |
| Kusunose | Report of the American College of Cardiology (ACC) scientific sessions 2014, Washington, DC | |
| TW202539680A (zh) | 組合物在製備用於治療至少一種癌症的用途 | |
| Kaidar-Person et al. | Radiation Therapy Effects |